246 related articles for article (PubMed ID: 30389699)
1. Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models.
Mair R; Mouliere F; Smith CG; Chandrananda D; Gale D; Marass F; Tsui DWY; Massie CE; Wright AJ; Watts C; Rosenfeld N; Brindle KM
Cancer Res; 2019 Jan; 79(1):220-230. PubMed ID: 30389699
[TBL] [Abstract][Full Text] [Related]
2. Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients.
Guo W; Jin L; Liang J; Lin G; Zheng J; Zhou D; Zhan S; Sun H; Jiang X
Clin Chim Acta; 2022 Sep; 534():81-92. PubMed ID: 35810802
[TBL] [Abstract][Full Text] [Related]
3. Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma.
Li JH; He ZQ; Lin FH; Chen ZH; Yang SY; Duan H; Jiang XB; Al-Nahari F; Zhang XH; Wang JH; Zhang GH; Zhang ZF; Li C; Mou YG
Mol Cell Probes; 2019 Aug; 46():101411. PubMed ID: 31173881
[TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.
Bagley SJ; Nabavizadeh SA; Mays JJ; Till JE; Ware JB; Levy S; Sarchiapone W; Hussain J; Prior T; Guiry S; Christensen T; Yee SS; Nasrallah MP; Morrissette JJD; Binder ZA; O'Rourke DM; Cucchiara AJ; Brem S; Desai AS; Carpenter EL
Clin Cancer Res; 2020 Jan; 26(2):397-407. PubMed ID: 31666247
[TBL] [Abstract][Full Text] [Related]
5. Assessment of circulating tumor DNA in cerebrospinal fluid by whole exome sequencing to detect genomic alterations of glioblastoma.
Duan H; Hu JL; Chen ZH; Li JH; He ZQ; Wang ZN; Zhang GH; Guo XY; Liang L; Mou YG
Chin Med J (Engl); 2020 Jun; 133(12):1415-1421. PubMed ID: 32558704
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
7. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
[TBL] [Abstract][Full Text] [Related]
8. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
[TBL] [Abstract][Full Text] [Related]
9. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
10. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of circulating tumor DNA from cerebrospinal fluid in recurrent high-grade glioma.
Fontanilles M; Deniel A; Marguet F; Beaussire L; Magne N; Derrey S; Blanchard F; Alexandru C; Coutant S; Laquerrière A; Clatot F; Di Fiore F; Sarafan-Vasseur N
Rev Neurol (Paris); 2022 Nov; 178(9):975-980. PubMed ID: 35871016
[TBL] [Abstract][Full Text] [Related]
12. Fragment Length of Circulating Tumor DNA.
Underhill HR; Kitzman JO; Hellwig S; Welker NC; Daza R; Baker DN; Gligorich KM; Rostomily RC; Bronner MP; Shendure J
PLoS Genet; 2016 Jul; 12(7):e1006162. PubMed ID: 27428049
[TBL] [Abstract][Full Text] [Related]
13. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer.
Santonja A; Cooper WN; Eldridge MD; Edwards PAW; Morris JA; Edwards AR; Zhao H; Heider K; Couturier DL; Vijayaraghavan A; Mennea P; Ditter EJ; Smith CG; Boursnell C; Manzano García R; Rueda OM; Beddowes E; Biggs H; Sammut SJ; Rosenfeld N; Caldas C; Abraham JE; Gale D
EMBO Mol Med; 2023 Jun; 15(6):e16505. PubMed ID: 37161793
[TBL] [Abstract][Full Text] [Related]
15. ctDNA monitoring using patient-specific sequencing and integration of variant reads.
Wan JCM; Heider K; Gale D; Murphy S; Fisher E; Mouliere F; Ruiz-Valdepenas A; Santonja A; Morris J; Chandrananda D; Marshall A; Gill AB; Chan PY; Barker E; Young G; Cooper WN; Hudecova I; Marass F; Mair R; Brindle KM; Stewart GD; Abraham JE; Caldas C; Rassl DM; Rintoul RC; Alifrangis C; Middleton MR; Gallagher FA; Parkinson C; Durrani A; McDermott U; Smith CG; Massie C; Corrie PG; Rosenfeld N
Sci Transl Med; 2020 Jun; 12(548):. PubMed ID: 32554709
[TBL] [Abstract][Full Text] [Related]
16. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
[TBL] [Abstract][Full Text] [Related]
17. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors.
Piccioni DE; Achrol AS; Kiedrowski LA; Banks KC; Boucher N; Barkhoudarian G; Kelly DF; Juarez T; Lanman RB; Raymond VM; Nguyen M; Truong JD; Heng A; Gill J; Saria M; Pingle SC; Kesari S
CNS Oncol; 2019 Jun; 8(2):CNS34. PubMed ID: 30855176
[No Abstract] [Full Text] [Related]
18. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer.
Zou D; Day R; Cocadiz JA; Parackal S; Mitchell W; Black MA; Lawrence B; Fitzgerald S; Print C; Jackson C; Guilford P
Carcinogenesis; 2020 Nov; 41(11):1507-1517. PubMed ID: 32955091
[TBL] [Abstract][Full Text] [Related]
20. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients.
Crisafulli G; Mussolin B; Cassingena A; Montone M; Bartolini A; Barault L; Martinetti A; Morano F; Pietrantonio F; Sartore-Bianchi A; Siena S; Di Nicolantonio F; Marsoni S; Bardelli A; Siravegna G
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32149725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
